ACELRX PHARMACEUTICALS INC | Business Contracts

Form of Securities Purchase Agreement, dated December 27, 2022 (Filed With SEC on December 29, 2022)

Non-Employee Director Compensation Policy (Filed With SEC on March 10, 2022)

License and Commercialization Agreement (PFS), dated July 14, 2021, between Laboratoire Aguettant and the Registrant (Filed With SEC on November 15, 2021)

Agreement and Plan of Merger, dated as of November 14, 2021, by and among the Registrant, Lowell, Merger Sub 1, Merger Sub 2 and the Stockholder Representative (Filed With SEC on November 15, 2021)

Form of CVR Agreement (Filed With SEC on November 15, 2021)

Commercial Supply Agreement, effective March 31, 2021 by and between Catalent Pharma Solutions, LLC and the Registrant (Filed With SEC on August 16, 2021)

Sublease for a Single Sublessee, dated March 26, 2021, by and between Weichert Workforce Mobility Inc., as successor in interest to The MI Group, Inc., and the Registrant (Filed With SEC on May 17, 2021)

Form of Common Warrant, as amended (November 2021) (Filed With SEC on December 29, 2022)

Form of Pre-Funded Warrant (December 2022) (Filed With SEC on December 29, 2022)

Form of Common Warrant (December 2022) (Filed With SEC on December 29, 2022)

Registration Rights Agreement, dated August 3, 2022, between AcelRx Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 4, 2022)

Securities Purchase Agreement, dated August 3, 2022, between AcelRx Pharmaceuticals, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 4, 2022)

Common Stock Purchase Warrant, dated August 3, 2022 (Filed With SEC on August 4, 2022)

Second Amendment to Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of November 14, 2021 (Filed With SEC on March 10, 2022)

Contingent Value Rights Agreement, dated as of January7, 2022, by and among AcelRx Pharmaceuticals, Inc., James Wilkie, solely in his capacity as the representative of the Lowell... (Filed With SEC on January 12, 2022)

License and Commercialization Agreement (DZUVEO), dated July 14, 2021, between Laboratoire Aguettant and the Registrant (Filed With SEC on November 15, 2021)

Form of Warrant (Filed With SEC on November 15, 2021)

First Amendment to Loan and Security Agreement, dated as of May 5, 2021, between Oxford Finance, LLC and the Registrant (Filed With SEC on November 15, 2021)

Purchase Agreement between the Company and the Purchasers, dated November 15, 2021 (Filed With SEC on November 15, 2021)

Amended and Restated 2020 Equity Incentive Plan (Filed With SEC on June 17, 2021)

Non-Employee Director Compensation Policy (Filed With SEC on May 17, 2021)

2021 Cash Bonus Plan Summary (Filed With SEC on May 17, 2021)

Non-Employee Director Compensation Policy (Filed With SEC on March 15, 2021)

2021 Cash Bonus Plan Summary (Filed With SEC on March 15, 2021)

Description of Capital Stock (Filed With SEC on March 15, 2021)

Underwriting Agreement (Filed With SEC on January 21, 2021)

Promotion Agreement among the Registrant, La Jolla Pharmaceutical Company and Tetraphase Pharmaceuticals, Inc., effective September 30, 2020 (Filed With SEC on November 5, 2020)

Distribution Agreement between the Registrant and Biomet 3i LLC d/b/a Zimmer Biomet Dental, dated July 17, 2020 (Filed With SEC on November 5, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on August 10, 2020)

Purchase Agreement between the Company and the Purchasers, dated July 22, 2020 (Filed With SEC on July 23, 2020)

Amendment No. 1 to Co-Promotion Agreement, dated as of May 26, 2020, by and between the Registrant and Tetraphase (Filed With SEC on May 29, 2020)

Form of Amendment No. 2 to Voting Agreement (Filed With SEC on May 29, 2020)

Form of Revised CVR Agreement (Filed With SEC on May 29, 2020)

Amendment No. 2 to Agreement and Plan of Merger, dated as of May 29, 2020, by and among the Registrant, Tetraphase and Merger Sub (Filed With SEC on May 29, 2020)

Amendment to Agreement and Plan of Merger, dated as of May 27, 2020, by and among the Registrant, Tetraphase and Merger Sub (Filed With SEC on May 27, 2020)

Form of Amendment to Voting Agreement (Filed With SEC on May 27, 2020)

Form of Revised CVR Agreement (Filed With SEC on May 27, 2020)

2020 Cash Bonus Plan Summary (Filed With SEC on May 11, 2020)

Consulting Agreement (Filed With SEC on April 8, 2020)

Transition Services Agreement and General Release (Filed With SEC on April 8, 2020)

2020 Cash Bonus Plan Summary (Filed With SEC on March 16, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on March 16, 2020)

Description of Capital Stock (Filed With SEC on March 16, 2020)

Amendment to Agreement between the Registrant and SpecGX, LLC, dated September 23, 2019 (Filed With SEC on November 7, 2019)

Agreement between the Registrant and SpecGX, LLC, dated June 16, 2017 (Filed With SEC on November 7, 2019)

Non-Employee Director Compensation Policy (Filed With SEC on August 6, 2019)

Form of Warrant to Purchase Common Stock of the Registrant, dated as of May 30, 2019 (Filed With SEC on June 3, 2019)

Loan and Security Agreement with Oxford Finance LLC, dated as of May 30, 2019 (Filed With SEC on June 3, 2019)

Sublease by and between Registrant and Genomic Health, Inc. dated as of November 30, 2018 (Filed With SEC on March 7, 2019)

2019 Cash Bonus Plan Summary (Filed With SEC on March 7, 2019)

ACELRX PHARMACEUTICALS INC (50)